Long non‑coding RNA FOXD2‑AS1 promotes proliferation, migration and invasion of ovarian cancer cells via regulating the expression of miR‑4492

Gao,Jianfen; Liu,Faqin; Zhao,Xia; Zhang,Ping

doi:10.3892/etm.2021.9738

Long non‑coding RNA FOXD2‑AS1 promotes proliferation, migration and invasion of ovarian cancer cells via regulating the expression of miR‑4492

Authors:
- Jianfen Gao
- Faqin Liu
- Xia Zhao
- Ping Zhang
View Affiliations

Affiliations: Department of Gynecology, People's Hospital of Zhangqiu District, Jinan, Shandong 250200, P.R. China, Operating Room, People's Hospital of Zhangqiu District, Jinan, Shandong 250200, P.R. China, Department of Obstetrics, People's Hospital of Zhangqiu District, Jinan, Shandong 250200, P.R. China, Department of Gynecology, Laizhou People's Hospital, Yantai, Shandong 261400, P.R. China
Published online on: February 1, 2021 https://doi.org/10.3892/etm.2021.9738
Article Number: 307

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine the role of long non‑coding RNA (lncRNA) forkhead box D2 antisense 1 (FOXD2‑AS1) in the development of ovarian cancer, investigate the underlying mechanisms and provide a potential diagnostic biomarker for ovarian cancer. A total of 39 ovarian cancer patients were included, and the ovarian cancer tissues and paracancer tissues were obtained. The ovarian cancer cell lines SKOV3 and OVCAR3 and the human ovarian normal epithelial cell line IOSE80 were cultured. The expression of lncRNA FOXD2‑AS1 and miR‑4492 was detected by reverse transcription‑quantitative PCR. Small interfering RNA targeting FOXD2‑AS1 (si‑FOXD2‑AS1), microRNA (miR)‑4492 mimics, miR‑4492 inhibitor and their corresponding controls were transfected into cells. The proliferation was detected with a Cell‑Couting‑Kit‑8 assay, and migration and invasion were determined using Transwell assays. The mutual binding site of lncRNA FOXD2‑AS1 and miR‑4492 was predicted with the miRDB database and verified by a luciferase reporter assay. Finally, a rescue assay was performed. The results suggested that lncRNA FOXD2‑AS1 was upregulated in ovarian cancer tissues and cell lines. si‑FOXD2‑AS1 was able to inhibit the proliferation, migration and invasion of ovarian cancer cells. lncRNA FOXD2‑AS1 was confirmed to directly target miR‑4492. The expression of lncRNA FOXD2‑AS1 and miR‑4492 exhibited a negative correlation. In a rescue experiment, miR‑4492 inhibitor abrogated the effect of siFOXD2‑AS1 in SKOV3 and OVCAR3 cell lines. In conclusion, lncRNA FOXD2‑AS1 promotes the proliferation and invasion of ovarian cancer cells via regulating the expression of miR‑4492. It may be a novel potential diagnostic biomarker and therapeutic target for ovarian cancer.

View Figures

View References

1	Golan A, Joosting AC and Orchard ME: Mumps virus and ovarian cancer. S Afr Med J. 56:18–20. 1979.PubMed/NCBI
2	Skates SJ, Menon U, Macdonald N, Rosenthal AN, Oram DH, Knapp RC and Jacobs IJ: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal Women. J Clin Oncol. 21 (10 Suppl):206s–210s. 2003.PubMed/NCBI View Article : Google Scholar
3	Makar AP and Tropé CG: Endometrial and ovarian malignancies: Epidemiology, etiology and prognostic factors. Acta Obstet Gynecol Scand. 71:331–336. 1992.PubMed/NCBI View Article : Google Scholar
4	Du K, Gong HY and Gong ZM: Influence of serum VEGF levels on therapeutic outcome and diagnosis/prognostic value in patients with cervical cancer. Asian Pac J Cancer Prev. 15:8793–8796. 2014.PubMed/NCBI View Article : Google Scholar
5	Suzuki M, Ohwara M, Sekiguchi I and Sato I: Radical cytoreductive surgery combined with platinums-carboplatin and cisplatin chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer. 9:54–60. 2010.
6	Slotman BJ and Rao BR: Ovarian cancer (review) Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res. 8:417–434. 1988.PubMed/NCBI
7	Tu H, Huang H, Huang QD, Li Z, Feng YL and Liu JH: Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence. Zhonghua Fu Chan Ke Za Zhi. 47:928–933. 2012.PubMed/NCBI(In Chinese).
8	Vance KW and Ponting CP: Transcriptional regulatory functions of nuclear long noncoding RNAs. Trends Genet. 30:348–355. 2014.PubMed/NCBI View Article : Google Scholar
9	Li Y, Zhang J, Huo C, Ding N, Li J, Xiao J, Lin X, Cai B, Zhang Y and Xu J: Dynamic organization of lncRNA and Circular RNA regulators collectively controlled cardiac differentiation in humans. Ebiomedicine. 24:137–146. 2017.PubMed/NCBI View Article : Google Scholar
10	Gao Y, Meng H, Liu S, Hu J, Zhang Y, Jiao T, Liu Y, Ou J, Wang D, Yao L, et al: LncRNA-HOST2 regulates cell biological behaviors in epithelial ovarian cancer through a mechanism involving microRNA let-7b. Hum Mol Genet. 24:841–852. 2015.PubMed/NCBI View Article : Google Scholar
11	Chai Y, Liu J, Zhang Z and Liu L: HuR-regulated lncRNA NEAT1 stability in tumorigenesis and progression of ovarian cancer. Cancer Med. 5:1588–1598. 2016.PubMed/NCBI View Article : Google Scholar
12	Liu E, Liu Z and Zhou Y: Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Int J Clin Exp Pathol. 8:3803–3810. 2015.PubMed/NCBI
13	Rong L, Zhao R and Lu J: Highly expressed long non-coding RNA FOXD2-AS1 promotes non-small cell lung cancer progression via Wnt/β-catenin signaling. Biochem Biophys Res Commun. 484:586–591. 2017.PubMed/NCBI View Article : Google Scholar
14	Yang X, Duan B and Zhou X: Long non-coding RNA FOXD2-AS1 functions as a tumor promoter in colorectal cancer by regulating EMT and Notch signaling pathway. Eur Rev Med Pharmacol Sci. 21:3586–3591. 2017.PubMed/NCBI
15	Bao J, Zhou C, Zhang J, Mo J, Ye Q, He J and Diao J: Upregulation of the long noncoding RNA FOXD2-AS1 predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Biomark. 21:527–533. 2018.PubMed/NCBI View Article : Google Scholar
16	Boo L, Ho WY, Ali NM, Yeap SK, Ky H, Chan KG, Yin WF, Satharasinghe DA, Liew WC, Tan SW, et al: MiRNA transcriptome profiling of spheroid-enriched cells with cancer stem cell properties in human breast MCF-7 cell line. Int J Biol Sci. 12:427–445. 2016.PubMed/NCBI View Article : Google Scholar
17	Egaña-Gorroño L, Guardo AC, Bargalló ME, Planet E, Vilaplana E, Escribà T, Pérez I, Gatell JM, García F, Arnedo M, et al: MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression. PLoS One. 11(e0155245)2016.PubMed/NCBI View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
19	Wang A, Jin C, Li H, Qin Q and Li L: LncRNA ADAMTS9-AS2 regulates ovarian cancer progression by targeting miR-182-5p/FOXF2 signaling pathway. Int J Biol Macromol. 120:1705–1713. 2018.PubMed/NCBI View Article : Google Scholar
20	Yan H, Li H, Li P, Li X, Lin J, Zhu L, Silva MA, Wang X, Wang P and Zhang Z: Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis. J Exp Clin Cancer Res. 37(237)2018.PubMed/NCBI View Article : Google Scholar
21	Soegaard M, Kjaer SK, Cox M, Wozniak E, Høgdall E, Høgdall C, Blaakaer J, Jacobs IJ, Gayther SA and Ramus SJ: BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res. 14:3761–3767. 2008.PubMed/NCBI View Article : Google Scholar
22	Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST and Farias-Eisner R: Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proc Natl Acad Sci USA. 100:12343–12348. 2003.PubMed/NCBI View Article : Google Scholar
23	Tsai MC, Spitale RC and Chang HY: Long intergenic noncoding RNAs: New links in cancer progression. Cancer Res. 71:3–7. 2011.PubMed/NCBI View Article : Google Scholar
24	Wang B, Liu M, Zhuang R, Jiang J, Gao J, Wang H, Chen H, Zhang Z, Kuang Y and Li P: Long non-coding RNA CCAT2 promotes epithelial-mesenchymal transition involving Wnt/β-catenin pathway in epithelial ovarian carcinoma cells. Oncol Lett. 15:3369–3375. 2018.PubMed/NCBI View Article : Google Scholar
25	Usongo M, Li X and Farookhi R: Activation of the canonical WNT signaling pathway promotes ovarian surface epithelial proliferation without inducing β-catenin/Tcf-mediated reporter expression. Dev Dyn. 242:291–300. 2013.PubMed/NCBI View Article : Google Scholar
26	An Q, Zhou L and Xu N: Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother. 103:415–420. 2018.PubMed/NCBI View Article : Google Scholar
27	Wang L, He J, Xu H, Xu L and Li N: MiR-143 targets CTGF and exerts tumor-suppressing functions in epithelial ovarian cancer. Am J Transl Res. 8:2716–2726. 2016.PubMed/NCBI
28	Chen G, Sun W, Hua X, Zeng W and Yang L: Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma carcinogenesis by modulating miR-363-5p/S100A1 pathway. Gene. 645:76–84. 2018.PubMed/NCBI View Article : Google Scholar
29	Tian T, Li X, Hua Z, Ma J, Liu Z, Chen H and Cui Z: S100A1 promotes cell proliferation and migration and is associated with lymph node metastasis in ovarian cancer. Discov Med. 23:235–245. 2017.PubMed/NCBI
30	Xun M, Ma CF, Du QL, Ji YH and Xu JR: Differential expression of miRNAs in enterovirus 71-infected cells. Virol J. 12(56)2015.PubMed/NCBI View Article : Google Scholar
31	Gavalas NG, Karadimou A, Dimopoulos MA and Bamias A: Immune response in ovarian cancer: How is the immune system involved in prognosis and therapy: Potential for treatment utilization. Clin Dev Immunol. 2010(791603)2011.PubMed/NCBI View Article : Google Scholar